UBS offers settlement to Telik over auction-rate securities(0)
Telik, the unprofitable Palo Alto developer of cancer and diabetes drugs that has built up an accumulated loss of $479.5 million, got some good news Friday, even if it is off a bit in the future. UBS, the financial firm, has agreed to buy Telik’s auction rate securities, which Telik has not had access to since the auctions for them froze up earlier this year. But Telik will have to wait unti Read the rest of this entry »
Subscribe via RSS all feeds